Tepotinib Approved by European Commission for Advanced MET exon 14+ NSCLC
The European Commission has approved tepotinib for use in patients with advanced non–small cell lung cancer with MET exon 14 skipping alterations.
First-Line Lorlatinib Receives Approval From the European Commission for ALK+ Advanced NSCLC
The European Commission approves the use of lorlatinib for the treatment of ALK-positive advanced non–small cell lung cancer.
Hong Kong Department of Health Approves Pemigatinib for Adults With FGFR2+ Locally Advanced/Metastatic Cholangiocarcinoma
Pemigatinib is a new treatment option following approval from the Hong Kong Department of Health for patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement following progression on at least 1 prior line of therapy.
Sotorasib Earns Approval in Japan for KRAS G12C+ NSCLC
The Japan Ministry of Health, Labour and Welfare granted approval to the KRAS inhibitor sotorasib for the treatment of adults with KRAS G12C–mutated non–small cell lung cancer.
Sugemalimab Study Meets Primary End Point for Refractory Extranodal Natural Killer/T-Cell Lymphoma, Moves Forward With NMPA of China
Sugemalimab showed promise in the phase 2 GEMSTONE-201 trial in a group of patients with extranodal natural killer/T-cell lymphoma; developer CStone is set to submit a new drug application for the treatment to the National Medical Products Administration of China.
